Rhythm Pharmaceuticals (RYTM) Cash from Financing Activities (2017 - 2026)

Rhythm Pharmaceuticals (RYTM) has 10 years of Cash from Financing Activities data on file, last reported at -$5.4 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$5.4 million, down 116.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $180.1 million (down 17.97% YoY), and the FY2025 annual result was $218.0 million, up 13.97% from the prior year.
• Cash from Financing Activities slipped to -$5.4 million in Q1 2026 per RYTM's latest filing, from -$2.9 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $189.3 million in Q3 2025 and troughed at -$5.4 million in Q1 2026.
• A 5-year average of $40.7 million and a median of $4.2 million in 2024 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities surged 38293.22% in 2022, then slumped 133.33% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $17.4 million in 2022, then plunged by 86.05% to $2.4 million in 2023, then surged by 1481.84% to $38.3 million in 2024, then sank by 107.69% to -$2.9 million in 2025, then tumbled by 83.18% to -$5.4 million in 2026.
• Business Quant data shows RYTM's Cash from Financing Activities at -$5.4 million in Q1 2026, -$2.9 million in Q4 2025, and $189.3 million in Q3 2025.